Elawyers Elawyers
Washington| Change

Chambers v. Boehringer Ingelheim Pharmaceuticals, Inc., 4:15-CV-68 (CDL). (2018)

Court: District Court, M.D. Georgia Number: infdco20180921b51 Visitors: 25
Filed: Sep. 20, 2018
Latest Update: Sep. 20, 2018
Summary: ORDER CLAY D. LAND , Chief District Judge . Plaintiff Virginia Chambers brought this products liability action against Defendant Boehringer Ingelheim Pharmaceuticals ("Boehringer") for alleged inadequate warnings and defective design regarding one of its products, Pradaxa. Plaintiff intends to offer articles written by Thomas J. Moore appearing in BMJ, a medical journal, as evidence in her case. Boehringer has filed a motion in limine to exclude Moore's articles. See Def.'s Mot. in Limi
More

ORDER

Plaintiff Virginia Chambers brought this products liability action against Defendant Boehringer Ingelheim Pharmaceuticals ("Boehringer") for alleged inadequate warnings and defective design regarding one of its products, Pradaxa. Plaintiff intends to offer articles written by Thomas J. Moore appearing in BMJ, a medical journal, as evidence in her case. Boehringer has filed a motion in limine to exclude Moore's articles. See Def.'s Mot. in Limine No. 13, ECF No. 72.

Last month, as part of related litigation in Connecticut state court, Boehringer deposed Mr. Moore. Before the deposition, Plaintiff moved for a protective order preventing Boehringer from designating any of that deposition testimony for use in this action, since the deposition took place after discovery closed. See Pl.'s Mot. for Protective Order & Objs., ECF No. 114. Because time was of the essence, the Court granted Plaintiff's motion before Boehringer could respond. See Order Granting Pl.'s Mot. for Protective Order (Aug. 28, `), ECF No. 115. But the Court provided that Boehringer could seek reconsideration of that order, which it promptly did. See Def.'s Mot. for Reconsid., ECF No. 116.

The Court concludes that if Plaintiff introduces Moore's articles, Boehringer should have the opportunity to present Moore's deposition testimony in response. Therefore, Boehringer's motion for reconsideration (ECF No. 116) is granted. Boehringer shall be permitted to designate Moore's deposition testimony for use in this trial, but it shall only be admissible if Plaintiff introduces Moore's articles.

Additionally, the parties have filed a joint motion to stay the pretrial deadlines related to deposition designations, counter-designations, and objections pending the Court's ruling on the parties' twenty-two motions in limine.1 See Joint Mot. to Amend Pretrial Deadline Regarding Dep. Designations, ECF No. 124. That motion is also granted. The Court hopes to rule on the parties' motions in limine, including Boehringer's motion to exclude Moore's articles, in advance of the November 1 pretrial conference.

IT IS SO ORDERED.

FootNotes


1. Though Plaintiff only filed two motions in limine, one is an "omnibus" motion that seeks to exclude five types of evidence. See Pl.'s Omnibus Mot. in Limine, ECF No. 58.
Source:  Leagle

Can't find what you're looking for?

Post a free question on our public forum.
Ask a Question
Search for lawyers by practice areas.
Find a Lawyer